SOX2 and head and neck squamous cell carcinoma: Finally, we found a within-patient difference metric between caveolin-1 and Sox-2 — calculated as the difference between the percentage of positivity of caveolin-1 and Sox-2 in a patient’s tumor sample — to be a strong predictive metric of cetuximab response in these patients with HNSCC (Figure 6F).